大黄牡丹汤加减治疗慢性盆腔炎湿热瘀结证的效果观察

Observation on the effect of modified Dahuang Mudan Decoction on chronic pelvic inflammation with damp-heat stasis syndrome

目的分析湿热瘀结证型慢性盆腔炎患者治疗需求,评价方剂大黄牡丹汤加减治疗的可行性。方法80例慢性盆腔炎患者,按照1∶1比例法分为对照组与观察组,各40例。对照组采用西药治疗,观察组采用中药大黄牡丹汤治疗。比较两组临床疗效、湿热瘀结证主症评分、中性粒细胞比例、白细胞计数、血清单核细胞趋化蛋白-1(MCP-1)、胰岛素样生长因子(IGF-1)水平。结果观察组治疗总有效率为95.00%,高于对照组的70.00%,差异具有统计学意义(P<0.05)。观察组湿热瘀结证主症总分(2.20±0.50)分、中性粒细胞比例(60.50±5.80)%、白细胞计数(5.28±0.50)×109/L、血清MCP-1(208.80±20.05)pg/ml、IGF-1(7.20±0.65)pg/ml,均低于对照组的(7.20±1.20)分、(64.20±6.30)%、(6.45±0.60)×109/L、(323.90±30.50)pg/ml、(10.50±1.05)pg/ml,差异具有统计学意义(P<0.05)。结论合理进行中西医结合治疗,可以在调节MCP-1、IGF-1水平的基础上抑制炎症反应,提升临床疗效。

Objective To analyze the treatment needs of patients with chronic pelvic inflammatory disease with damp-heat stasis syndrome,so as to evaluate the feasibility of modified Dahuang Mudan Decoction.Methods A total of 80 patients with chronic pelvic inflammatory disease with damp-heat stasis syndrome were divided into control group and observation group according to the ratio of 1∶1,with 40 cases in each group.The control group was treated with Western medicine,and the observation group was treated with traditional Chinese medicine of modified Dahuang Mudan Decoction.The clinical efficacy,main symptom score of damp-heat stasis syndrome,neutrophil ratio,leukocyte count,serum monocyte chemoattractant protein-1(MCP-1)and insulin-like growth factor-1(IGF-1)were compared between the two groups.Results The total effective rate in the observation group was 95.00%,which was higher than 70.00%in the control group,and the difference was statistically significant(P<0.05).The total score of main symptom score of damp-heat stasis syndrome(2.20±0.50)points,neutrophil ratio(60.50±5.80)%,white blood cell count(5.28±0.50)×109/L,serum MCP-1(208.80±20.05)pg/ml and IGF-1(7.20±0.65)pg/ml of the observation group were lower than(7.20±1.20)points,(64.20±6.30)%,(6.45±0.60)×109/L,(323.90±30.50)pg/ml,(10.50±1.05)pg/ml of the control group,and the difference was statistically significant(P<0.05).Conclusion Reasonable treatment with integrated traditional Chinese and Western medicine can inhibit inflammation response on the basis of regulating the levels of MCP-1 and IGF-1 and improve clinical efficacy.